At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Closed 08-13 16:00:00 EDT
1.34
-0.04
-2.90%
盘后1.35
+0.01+0.75%
19:50 EDT
High1.39Low1.34Vol179.09K
Open1.36D1 Closing1.38Amplitude3.26%
Mkt Cap81.30MTradable Cap68.72MTotal Shares60.67M
T/O243.67KT/O Rate0.35%Tradable Shares51.28M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
Benzinga Earnings  ·  08-10
MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
Maia Biotech Q2 FY26 Net Loss Widens 49% to $7.94 Million
Reuters  ·  08-10
Maia Biotech Q2 FY26 Net Loss Widens 49% to $7.94 Million
Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA)
TIPRANKS  ·  07-10
Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA)
Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr in 3l Nsclc
Reuters  ·  07-08
Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr in 3l Nsclc
MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion
TIPRANKS  ·  07-08
MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion
Maia Biotech Reports 90.5% Disease Control Rate in Phase 2 Third-line NSCLC Trial Expansion
Reuters  ·  07-08
Maia Biotech Reports 90.5% Disease Control Rate in Phase 2 Third-line NSCLC Trial Expansion
Maia Biotechnology - Ateganosine Plus Cemiplimab Shows Acceptable Safety Profile in Heavily Pre-treated Patients
THOMSON REUTERS  ·  07-08
Maia Biotechnology - Ateganosine Plus Cemiplimab Shows Acceptable Safety Profile in Heavily Pre-treated Patients
Maia Biotechnology Reports Strong Initial Efficacy Data in Third-line Non-small Cell Lung Cancer from Phase 2 Thio-101 Part C Expansion Trial
THOMSON REUTERS  ·  07-08
Maia Biotechnology Reports Strong Initial Efficacy Data in Third-line Non-small Cell Lung Cancer from Phase 2 Thio-101 Part C Expansion Trial
Maia Biotechnology - Thio-101 Part C Shows 90.5% Disease Control Rate in 3L Nsclc
THOMSON REUTERS  ·  07-08
Maia Biotechnology - Thio-101 Part C Shows 90.5% Disease Control Rate in 3L Nsclc
Maia Biotechnology - Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr in 3L Nsclc
THOMSON REUTERS  ·  07-08
Maia Biotechnology - Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr in 3L Nsclc
Maia Biotechnology Completes International Enrollment in Part C of Phase 2 Thio-101 Expansion Trial in Third-line Non-small Cell Lung Cancer
THOMSON REUTERS  ·  06-25
Maia Biotechnology Completes International Enrollment in Part C of Phase 2 Thio-101 Expansion Trial in Third-line Non-small Cell Lung Cancer
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
GlobeNewswire  ·  06-25
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
Maia Biotech opens enrollment at Emory Winship for Phase 2 ateganosine NSCLC trial
Reuters  ·  06-18
Maia Biotech opens enrollment at Emory Winship for Phase 2 ateganosine NSCLC trial
Maia Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
THOMSON REUTERS  ·  06-18
Maia Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
Compugen to Unveil Latest Data from MAIA Ovarian Cancer Drug Trial at European Conference
Deep News  ·  06-11
Compugen to Unveil Latest Data from MAIA Ovarian Cancer Drug Trial at European Conference
Maia Biotech opens enrollment at second US site for Phase 2 THIO-101 lung cancer trial expansion
Reuters  ·  06-10
Maia Biotech opens enrollment at second US site for Phase 2 THIO-101 lung cancer trial expansion
Maia Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 Thio-101 Expansion Trial
THOMSON REUTERS  ·  06-10
Maia Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 Thio-101 Expansion Trial
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
GlobeNewswire  ·  06-10
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial
TIPRANKS  ·  06-04
MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial
MAIA Biotech doses 29 patients in Phase 3 THIO-104 lung cancer trial
Reuters  ·  06-04
MAIA Biotech doses 29 patients in Phase 3 THIO-104 lung cancer trial

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--